Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device company offering an innovative therapeutic approach to “stasis and barrier applications.” This means improved time to cessation of bleeding (hemostasis) and the control of fluid leakage (sealant) during surgery and trauma care.
Arch intends to transform the landscape of interventional healthcare with novel products to seal and protect tissue. Arch’s flagship product known as the AC5 Surgical Hemostatic Device is designed to elegantly achieve hemostasis in minimally invasive (laparoscopic) and open surgical procedures.
In preclinical tests, AC5 has been found to be simple, effective, and versatile. SNNLive spoke with Terrence Norchi, MD, President and CEO of Arch Therapeutics, Inc. at the LD Micro Invitational 2014 in Bel Air, CA.
“Arch is a medical technology company based in Wellesley, Massachusetts right outside Boston. We’re developing novel solutions to stop bleeding during surgery and trauma,” begins Dr. Norchi.
He continues, “We have a technology that we’ve licensed from MIT called self-assembling peptides, and the peptides are very exciting in that they build themselves into a physical mechanical structure when you squirt them onto a bleeding wound and that structure actually acts as a barrier to stop the bleeding.”
Dr. Norchi explains, “We’re focused on surgery first rather than trauma and we’re focused on specifically bleeding rather than some of the places that you can use this in the body that are sealant applications.” For more information, check out their website at www.archtheapeutics.com
© 2017 Stock News Now
Supported by Superior Web Solutions